Last reviewed · How we verify
ACULAR
Acular (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain.
Acular (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain. Used for Ocular pain and inflammation following ophthalmic surgery, Temporary relief of ocular itching due to seasonal allergic conjunctivitis.
At a glance
| Generic name | ACULAR |
|---|---|
| Also known as | Acular LS 0.4% 5 mL, - from Allergan, Apo-Ketorolac® Ophthalmic |
| Sponsor | University of South Alabama |
| Drug class | NSAID (nonsteroidal anti-inflammatory drug) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ketorolac works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels in ocular tissues, it provides rapid anti-inflammatory and analgesic effects. It is commonly used as an ophthalmic formulation for short-term management of ocular pain and inflammation.
Approved indications
- Ocular pain and inflammation following ophthalmic surgery
- Allergic conjunctivitis
- Postoperative ocular inflammation
Common side effects
- Ocular irritation or stinging
- Headache
- Transient corneal erosion
- Allergic reactions
Key clinical trials
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting (NA)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries (NA)
- Anesthetics and Analgesics in Children
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACULAR CI brief — competitive landscape report
- ACULAR updates RSS · CI watch RSS
- University of South Alabama portfolio CI